公众号 / 文章儿科影像外周血管心血管MR

Ferumoxytol增强MRI在儿童和青年中的应用现状

Ferumoxytol-Enhanced MRI in Children and Young Adults: State of the Art.
PubMed 文献 · AJR Am J Roentgenol · 2022-10-05

Ferumoxytol是一种超小氧化铁纳米颗粒,原用于成人慢性肾病缺铁治疗,后被超说明书用作MRI对比剂,尤其在北美儿科患者中应用增多。本文基于作者机构经验,阐述其在儿童和青年血管、心脏和肿瘤成像中的临床与早期转化应用,并介绍细胞分子成像及作为潜在抗癌治疗剂的研究进展。

要点

  • Ferumoxytol无钆对比剂相关的肾源性系统性纤维化风险,且在铁代谢正常者中无长期组织滞留。
  • 其长血管滞留特性利于高质量血管成像,网状内皮系统滞留支持多种超越钆对比剂的应用。
  • 儿童和青年中超说明书使用Ferumoxytol增强MRI的临床与转化应用正在拓展。

关键影像表现/征象

  • Ferumoxytol具有长血管滞留特性,可支持高质量血管成像。
  • Ferumoxytol可滞留于网状内皮系统组织,支持超越钆对比剂的应用。
  • Ferumoxytol在铁代谢正常患者中无长期组织滞留。

临床应用与阅片要点

  • 可关注Ferumoxytol在儿童和青年血管、心脏及肿瘤成像中的超说明书应用。
  • 利用其长血管滞留特性优化血管成像质量。
  • 注意其无肾源性系统性纤维化风险且无长期组织滞留的特点。

局限性

  • 本文为临床观点类文章,主要基于作者机构经验,非系统研究。
  • Ferumoxytol在儿童和青年中的使用为超说明书应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Ferumoxytol is an ultrasmall iron oxide nanoparticle that was originally approved by the FDA in 2009 for IV treatment of iron deficiency in adults with chronic kidney disease. Subsequently, its off-label use as an MRI contrast agent increased in clinical practice, particularly in pediatric patients in North America. Unlike conventional MRI contrast agents that are based on the rare earth metal gadolinium (gadolinium-based contrast agents), ferumoxytol is biodegradable and carries no potential risk of nephrogenic systemic fibrosis. At FDA-approved doses, ferumoxytol shows no long-term tissue retention in patients with intact iron metabolism. Ferumoxytol provides unique MRI properties, including long-lasting vascular retention (facilitating high-quality vascular imaging) and retention in reticuloendothelial system tissues, thereby supporting a variety of applications beyond those possible with gadolinium-based contrast agents (GBCAs). This Clinical Perspective describes clinical and early translational applications of ferumoxytol-enhanced MRI in children and young adults through off-label use in a variety of settings, including vascular, cardiac, and cancer imaging, drawing on the institutional experience of the authors. In addition, we describe current advances in pre-clinical and clinical research using ferumoxytol in cellular and molecular imaging as well as the use of ferumoxytol as a novel potential cancer therapeutic agent.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Adams, Jayapal, Ramasamy, et al. Ferumoxytol-Enhanced MRI in Children and Young Adults: State of the Art. AJR Am J Roentgenol. 2022. PMID: 36197052. doi:10.2214/AJR.22.28453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。